Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy

Immunotherapy has revolutionized cancer treatment. Immune-checkpoint inhibitors, on balance, showed a favorable efficacy/toxicity profile with durable response in different cancer types. No predictive biomarker has been validated thus far to select patients who would benefit from therapy. Among the...

Descripción completa

Detalles Bibliográficos
Autores principales: Viale, Giulia, Trapani, Dario, Curigliano, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523547/
https://www.ncbi.nlm.nih.gov/pubmed/28770222
http://dx.doi.org/10.1155/2017/4719194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523547/
https://www.ncbi.nlm.nih.gov/pubmed/28770222
http://dx.doi.org/10.1155/2017/4719194

Ejemplares similares